Practice Test Geeks(ADM) Board Certified Addiction Medicine Specialist Practice Test
← All ADM Flashcard Decks

Treatment Protocols & Procedures Flashcards

7 cards from real ADM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Treatment Protocols & Procedures flashcards as text

  1. A patient with opioid use disorder is starting buprenorphine. Which condition must be met before administering the first dose to avoid precipitated withdrawal?

    Answer: The patient must be in mild-to-moderate opioid withdrawal (COWS ≥8)

    Buprenorphine induction requires the patient to be in at least mild withdrawal (COWS ≥8) to prevent precipitated withdrawal from its partial agonist/antagonist properties.

  2. Which naltrexone formulation is preferred for opioid use disorder in patients with adherence concerns and no hepatic impairment?

    Answer: Extended-release injectable naltrexone (Vivitrol) monthly

    Extended-release injectable naltrexone (Vivitrol) eliminates the daily adherence issue and maintains consistent plasma levels for the full month.

  3. A patient on methadone maintenance presents with QTc of 510 ms on ECG. What is the most appropriate next step?

    Answer: Reduce the methadone dose and consider switching to buprenorphine

    QTc >500 ms is a serious concern with methadone; dose reduction or transition to buprenorphine is indicated to reduce arrhythmia risk.

  4. According to ASAM criteria, which level of care is appropriate for a patient with alcohol use disorder who has mild withdrawal symptoms, stable vital signs, and strong social support at home?

    Answer: Level 1: Outpatient treatment

    Mild withdrawal with stable vitals and strong support qualifies for outpatient treatment (ASAM Level 1) with close monitoring.

  5. Which medication is FDA-approved specifically for the treatment of alcohol use disorder and works by blocking opioid receptors to reduce craving?

    Answer: Naltrexone

    Naltrexone blocks opioid receptors involved in alcohol-induced reward, reducing craving and the pleasurable effects of drinking.

  6. A patient with stimulant use disorder is seeking pharmacotherapy. Which of the following has the strongest evidence base as a treatment option?

    Answer: There is currently no FDA-approved medication for stimulant use disorder

    No medication is currently FDA-approved for stimulant use disorder, though several show promise in clinical trials (e.g., bupropion + naltrexone for methamphetamine).

  7. Which withdrawal syndrome poses the greatest immediate risk of mortality if untreated?

    Answer: Alcohol withdrawal

    Alcohol withdrawal can progress to delirium tremens with seizures and cardiovascular collapse, carrying significant mortality risk without treatment.